Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.
Allena’s proprietary technological approach enables the design, formulation and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. This approach utilizes the GI tract to degrade metabolites, such as oxalate and urate, reducing plasma and urine levels, and in turn, reducing their disease burden on the kidney over time.
See our social media community guidelines - https://www.allenapharma.com/social-media-community-guidelines
|
|
|
|
|
1-10 employees
View all Allena Pharmaceuticals, Inc. employees
|
|
|
Biotechnology
|
|
|
$10M–$50M
|
|
|
(617) 965-8500
|
|
|
One Newton Executive Park, Suite 202, Newton, MA 02462, US
|
|
|
2011
|
|
|
Specific Nonabsorbed Oral Enzyme Therapeutics And Oral Biologics
|
The decision makers in Allena Pharmaceuticals, Inc. are April Effort, Boris Kandinov, Boris Kandinov, etc. Click to Find Allena Pharmaceuticals, Inc. decision makers emails.
Allena Pharmaceuticals, Inc. headquarters is located at One Newton Executive Park, Suite 202, Newton, MA 02462, US.
Allena Pharmaceuticals, Inc. generates an estimated $10M–$50M annually, based on industry analysis and publicly available market data.
You can contact Allena Pharmaceuticals, Inc. by calling (617) 965-8500.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.